The advent of immunotherapy approaches have significantly improved clinical outcomes in many cancer types. However, they are still not an option for all cancers and all patients. The dismal response rates to single-agent immune therapies, acquired resistance and suboptimal activity of immune responses against a range of tumors pose a huge therapeutic challenge.
Strategic re-tuning of the highly suppressive TME is an elegant consideration to counter these clinical gaps.
We are leveraging our deep medicinal chemistry expertise in the design of ‘Next-Generation’ small molecule therapeutics in immuno-oncology, with inhibitors of extracellular adenosine (eADO) generation and signalling that regulate both innate and adaptive anti-tumor immune responses.